Patents by Inventor Dilip K. Tosh
Dilip K. Tosh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220024926Abstract: Disclosed are compounds of the formulas (I), (II), and (II): which are A1 adenosine receptor agonists, pharmaceutical compositions comprising such compounds, and a method of use of these compounds, wherein Y, R1-R6, R10-R15, and R20-R22 are as defined in the specification. These compounds are selective to the A1 adenosine receptor, and are contemplated for use in the treatment or prevention of a number of diseases or conditions, for example, for inducing and/or maintaining a hypothermic and/or hypometabolic state for treatment of a mammal.Type: ApplicationFiled: December 6, 2019Publication date: January 27, 2022Applicant: The United States of America,as represented by the Secretary,Department of Health and Human ServicesInventors: Kenneth A. Jacobson, Dilip K. Tosh, Marc L. Reitman, Oksana Gavrilova
-
Patent number: 10577368Abstract: Disclosed are compounds of the formula (I) and (II): which are A3 adenosine receptor agonists, pharmaceutical compositions comprising such compounds, and a method of use of these compounds, wherein X, Y, Z, R2-R6, and R103-R106 are as defined in the specification. These compounds are selective to the A3 receptor, and are contemplated for use in the treatment or prevention of a number of diseases or conditions, for example, neuropathic pain.Type: GrantFiled: April 10, 2018Date of Patent: March 3, 2020Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Saint Louis UniversityInventors: Kenneth A. Jacobson, Dilip K. Tosh, Daniela Salvemini
-
Publication number: 20180230150Abstract: Disclosed are compounds of the formula (I) and (II): which are A3 adenosine receptor agonists, pharmaceutical compositions comprising such compounds, and a method of use of these compounds, wherein X, Y, Z, R2-R6, and R103-R106 are as defined in the specification. These compounds are selective to the A3 receptor, and are contemplated for use in the treatment or prevention of a number of diseases or conditions, for example, neuropathic pain.Type: ApplicationFiled: April 10, 2018Publication date: August 16, 2018Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Serv, Saint Louis UniversityInventors: Kenneth A. Jacobson, Dilip K. Tosh, Daniela Salvemini
-
Patent number: 9963450Abstract: Disclosed are compounds of the formula (I) and (II) which are A3 adenosine receptor agonists, pharmaceutical compositions comprising such compounds, and a method of use of these compounds, wherein X, Y, Z, R2-R6, and R103-R106 are as defined in the specification. These compounds are selective to the A3 receptor, and are contemplated for use in the treatment or prevention of a number of diseases or conditions, for example, neuropathic pain.Type: GrantFiled: November 20, 2014Date of Patent: May 8, 2018Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Saint Louis UniversityInventors: Kenneth A. Jacobson, Dilip K. Tosh, Daniela Salvemini
-
Publication number: 20170002007Abstract: Disclosed are compounds of the formula (I) and (II) which are A3 adenosine receptor agonists, pharmaceutical compositions comprising such compounds, and a method of use of these compounds, wherein X, Y, Z, R2-R6, and R103-R106 are as defined in the specification. These compounds are selective to the A3 receptor, and are contemplated for use in the treatment or prevention of a number of diseases or conditions, for example, neuropathic pain.Type: ApplicationFiled: November 20, 2014Publication date: January 5, 2017Inventors: Kenneth A. Jacobson, Dilip K. Tosh, Daniela Salvemini
-
Patent number: 9181253Abstract: Disclosed are A3 adenosine receptor antagonists and/or partial agonists and A1 adenosine receptor agonists and/or partial agonists of formula (I): wherein R1 to R5 are as described herein, as well as pharmaceutical compositions thereof and methods of use thereof. The A3 AR antagonists or partial agonists find use in treating a number of diseases such as cancer, glaucoma, and inflammatory diseases, as well as in preventing cardiac ischemia. Also disclosed are radiolabeled compounds of formula (I) and the use thereof in diagnostic imaging of tissues and organs. The A1 AR agonists and partial agonists find use in treating diseases such as seizures, convulsion, stroke, diabetes, pain, arrhythmias, depression, and anxiety and in cardioprotection or neuroprotection.Type: GrantFiled: May 24, 2012Date of Patent: November 10, 2015Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Kenneth A. Jacobson, Dilip K. Tosh
-
Patent number: 8916570Abstract: Disclosed are (N)-methanocarba adenine nucleosides of formulas (I)-(V), for example, of formula (V): as highly potent A3 adenosine receptor agonists, pharmaceutical compositions comprising such nucleosides, and a method of use of these nucleosides, wherein R1-R6 are as defined in the specification. These nucleosides exhibit similar selectivities as agonists of the A3 versus the A1 receptor for both human and mouse adenosine receptors, and are contemplated for use in the treatment a number of diseases, for example, inflammation, cardiac ischemia, stroke, asthma, diabetes, and cardiac arrhythmias.Type: GrantFiled: February 10, 2012Date of Patent: December 23, 2014Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Kenneth A. Jacobson, Dilip K. Tosh
-
Patent number: 8518957Abstract: Disclosed are (N)-methanocarba adenine nucleosides, e.g., of the formula (I): as A3 adenosine receptor agonists, pharmaceutical compositions comprising such nucleosides, and a method of use of these nucleosides, wherein A, a, R2, and R3 are as defined in the specification. These nucleosides are contemplated for use in the treatment a number of diseases, for example, inflammation, cardiac ischemia, stroke, asthma, diabetes, and cardiac arrhythmias. Also disclosed are conjugates comprising a dendrimer and one or more ligands, which are functionalized congeners of an agonist or antagonist of a receptor of the G-protein coupled receptor (GPCR) superfamily. Such conjugates are have the potential of being used as dual agonists, dual antagonists, or agonist/antagonist combinations.Type: GrantFiled: December 2, 2010Date of Patent: August 27, 2013Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Kenneth A. Jacobson, Dilip K. Tosh
-
Publication number: 20120264769Abstract: Disclosed are (N)-methanocarba adenine nucleosides, e.g., of the formula (I): as A3 adenosine receptor agonists, pharmaceutical compositions comprising such nucleosides, and a method of use of these nucleosides, wherein A, a, R2, and R3 are as defined in the specification. These nucleosides are contemplated for use in the treatment a number of diseases, for example, inflammation, cardiac ischemia, stroke, asthma, diabetes, and cardiac arrhythmias. Also disclosed are conjugates comprising a dendrimer and one or more ligands, which are functionalized congeners of an agonist or antagonist of a receptor of the G-protein coupled receptor (GPCR) superfamily. Such conjugates are have the potential of being used as dual agonists, dual antagonists, or agonist/antagonist combinations.Type: ApplicationFiled: December 2, 2010Publication date: October 18, 2012Applicant: The United States of Americia, as represented by the Secretary, Department of Health and Human ServInventors: Kenneth A. Jacobson, Dilip K. Tosh
-
Publication number: 20120252823Abstract: Disclosed are A3 adenosine receptor antagonists and/or partial agonists and A1 adenosine receptor agonists and/or partial agonists of formula (I): wherein R1 to R5 are as described herein, as well as pharmaceutical compositions thereof and methods of use thereof. The A3 AR antagonists or partial agonists find use in treating a number of diseases such as cancer, glaucoma, and inflammatory diseases, as well as in preventing cardiac ischemia. Also disclosed are radiolabeled compounds of formula (I) and the use thereof in diagnostic imaging of tissues and organs. The A1 AR agonists and partial agonists find use in treating diseases such as seizures, convulsion, stroke, diabetes, pain, arrhythmias, depression, and anxiety and in cardioprotection or neuroprotection.Type: ApplicationFiled: May 24, 2012Publication date: October 4, 2012Applicants: ServicesInventors: Kenneth A. Jacobson, Dilip K. Tosh
-
Publication number: 20120184569Abstract: Disclosed are (N)-methanocarba adenine nucleosides of formulas (I)-(V), for example, of formula (V): as highly potent A3 adenosine receptor agonists, pharmaceutical compositions comprising such nucleosides, and a method of use of these nucleosides, wherein R1-R6 are as defined in the specification. These nucleosides exhibit similar selectivities as agonists of the A3 versus the A1 receptor for both human and mouse adenosine receptors, and are contemplated for use in the treatment a number of diseases, for example, inflammation, cardiac ischemia, stroke, asthma, diabetes, and cardiac arrhythmias.Type: ApplicationFiled: February 10, 2012Publication date: July 19, 2012Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human ServicesInventors: Kenneth A. Jacobson, Dilip K. Tosh